{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:58:25Z","timestamp":1776761905974,"version":"3.51.2"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA205727"],"award-info":[{"award-number":["R21CA205727"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00634","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T05:07:30Z","timestamp":1586927250000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses"],"prefix":"10.3389","volume":"11","author":[{"given":"Qiuxia","family":"Qu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieni","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cam4.371","article-title":"CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations","volume":"4","author":"Camacho","year":"2015","journal-title":"Cancer Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41422-018-0012-z","article-title":"Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/stem.5530160831","article-title":"Cytokine gene transfer in cancer therapy","volume":"16","author":"Cao","year":"1998","journal-title":"Stem Cells."},{"key":"B5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s002620050464","article-title":"Tumor immunotherapy: cytokines and antigen presentation","volume":"46","author":"Lord","year":"1998","journal-title":"Cancer Immunol Immunother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/A:1008304721889","article-title":"Cytokine gene therapy: hopes and pitfalls","volume":"10","author":"Nanni","year":"1999","journal-title":"Ann Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00109-016-1397-0","article-title":"Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy","volume":"94","author":"Lu","year":"2016","journal-title":"J Mol Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fimmu.2019.00263","article-title":"Fueling cancer immunotherapy with common gamma chain cytokines","volume":"10","author":"Dwyer","year":"2019","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.smim.2013.11.003","article-title":"Biology of IL-36 cytokines and their role in disease","volume":"25","author":"Gresnigt","year":"2013","journal-title":"Semin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/jid.2011.482","article-title":"The double-stranded RNA analogue polyinosinic-polycytidylic acid induces keratinocyte pyroptosis and release of IL-36gamma","volume":"132","author":"Lian","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1182\/blood-2011-05-356873","article-title":"IL-36R ligands are potent regulators of dendritic and T cells","volume":"118","author":"Vigne","year":"2011","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/eji.201142035","article-title":"Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9","volume":"42","author":"Mutamba","year":"2012","journal-title":"Eur J Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood-2012-06-439026","article-title":"IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells","volume":"120","author":"Vigne","year":"2012","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ccell.2015.07.014","article-title":"IL-36gamma transforms the tumor microenvironment and promotes type 1 lymphocyte-mediated antitumor immune responses","volume":"28","author":"Wang","year":"2015","journal-title":"Cancer Cell."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.4049\/jimmunol.167.3.1440","article-title":"Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2","volume":"167","author":"Debets","year":"2001","journal-title":"J Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1084\/jem.20070157","article-title":"Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation","volume":"204","author":"Blumberg","year":"2007","journal-title":"J Exp Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s11596-013-1164-1","article-title":"IL-36 cytokine expression and its relationship with p38 MAPK and NF-kappaB pathways in psoriasis vulgaris skin lesions","volume":"33","author":"He","year":"2013","journal-title":"J Huazhong Univ Sci Technolog Med Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J Clin Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1152\/physiolgenomics.00289.2004","article-title":"Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense","volume":"21","author":"Vos","year":"2005","journal-title":"Physiol Genomics."},{"key":"B23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1165\/rcmb.2010-0075OC","article-title":"Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells","volume":"45","author":"Chustz","year":"2011","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"41684","DOI":"10.1074\/jbc.M112.385443","article-title":"IL-36gamma\/IL-1F9, an innate T-bet target in myeloid cells","volume":"287","author":"Bachmann","year":"2012","journal-title":"J Biol Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/eji.201242711","article-title":"The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses","volume":"43","author":"Gresnigt","year":"2013","journal-title":"Eur J Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s00262-013-1471-1","article-title":"Decreased expression of interleukin-36alpha correlates with poor prognosis in hepatocellular carcinoma","volume":"62","author":"Pan","year":"2013","journal-title":"Cancer Immunol Immunother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4049\/jimmunol.1501217","article-title":"Costimulation endows immunotherapeutic CD8 T cells with IL-36 responsiveness during aerobic glycolysis","volume":"196","author":"Tsurutani","year":"2016","journal-title":"J Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1322238","DOI":"10.1080\/2162402X.2017.1322238","article-title":"Tbet and IL-36gamma cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment","volume":"6","author":"Weinstein","year":"2017","journal-title":"Oncoimmunology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.nano.2018.09.005","article-title":"Targeted codelivery of doxorubicin and IL-36gamma expression plasmid for an optimal chemo-gene combination therapy against cancer lung metastasis","volume":"15","author":"Chen","year":"2019","journal-title":"Nanomedicine."},{"key":"B30","doi-asserted-by":"publisher","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci Transl Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00262-018-2259-0","article-title":"Association of IL-36gamma with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer","volume":"68","author":"Weinstein","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/mi.2017.21","article-title":"IL-36gamma signaling controls the induced regulatory T cell-Th9 cell balance via NFkappaB activation and STAT transcription factors","volume":"10","author":"Harusato","year":"2017","journal-title":"Mucosal Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell."},{"key":"B36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrd1775","article-title":"Design and development of polymers for gene delivery","volume":"4","author":"Pack","year":"2005","journal-title":"Nat Rev Drug Discov."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1073\/pnas.1801524115","article-title":"Anti-CTLA-4 therapy requires an Fc domain for efficacy","volume":"115","author":"Ingram","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science."},{"key":"B39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity."},{"key":"B41","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4049\/jimmunol.155.3.1032","article-title":"Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4","volume":"155","author":"Kearney","year":"1995","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/intimm\/8.4.519","article-title":"Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo","volume":"8","author":"Krummel","year":"1996","journal-title":"Int Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity."},{"key":"B45","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science."},{"key":"B46","doi-asserted-by":"publisher","first-page":"9296","DOI":"10.1073\/pnas.94.17.9296","article-title":"Thymocyte development is normal in CTLA-4-deficient mice","volume":"94","author":"Chambers","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science."},{"key":"B48","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science."},{"key":"B49","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12180","article-title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma","volume":"1291","author":"Wolchok","year":"2013","journal-title":"Ann NY Acad Sci."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00634\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T23:10:50Z","timestamp":1696029050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00634\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2020.00634"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00634","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"article-number":"634"}}